Meeting
2019 ASCO Annual Meeting
Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma.
Authors
Nitya Prabhakar Raj
Memorial Sloan Kettering Cancer Center, New York, NY
Nitya Prabhakar Raj , Youyun Zheng , Virginia Kelly , Seth Katz , Joanne F Chou , Richard K. G. Do , Marinela Capanu , Dmitriy Zamarin , Charlotte Eielson Ariyan , Brian R. Untch , Eileen Mary O'Reilly , Anuradha Gopalan , Michael F. Berger , Kelly Olino , Neil Howard Segal , Diane Lauren Reidy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Clinical Trial Registration Number
NCT02673333
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4112)
DOI
10.1200/JCO.2019.37.15_suppl.4112
Abstract #
4112
Poster Bd #
217
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).
First Author: Igor Puzanov
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2023 ASCO Annual Meeting
KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.
First Author: Sun Young Rha
Poster
2021 ASCO Annual Meeting
A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
First Author: Elena Garralda